Strahlentherapie des Mediastinalen Hodgkin-Lymphoms

Literaturverzeichnis
Dorffel, W., Luders, H., Ruhl, U., Albrecht, M., Marciniak, H., Parwaresch, R., Potter, R., Schellong, G.,
Schwarze, E.W., and Wickmann, L. (2003). Preliminary results of the multicenter trial GPOH-HD 95 for the
treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 215, 139-145.
Duggan, D.B., Petroni, G.R., Johnson, J.L., Glick, J.H., Fisher, R.I., Connors, J.M., Canellos, G.P., and Peterson,
B.A. (2003). Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced
Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21, 607-614.
Ebstein, W. (1887). Von das chronische ruckfallsfieber, eine neu infections-krankheit. Berl Klin Wochenschr 24,
565.
Eghbali, H., Raemaekers, J., and Carde, P. (2005). The EORTC strategy in the treatment of Hodgkin's
lymphoma. European Journal of Haematology 75, 135-140.
Eich, H., Engert, A., Haverkamp, H., Staar, S., Kriz, J., Engenhart-Cabillic, R., Lukas, P., Willich, N., Diehl, V.,
and Mueller, R. (2009). Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated
followed by 4 Cycles of BEACOPP Baseline with or without Radiotherapy in Patients in Advanced-stage
Hodgkin Lymphoma (HL): Final Analysis of the Randomized HD12 Trial of the German Hodgkin Study Group
(GHSG). Int J Radiat Oncol Biol Phys 75, S3-S4.
Eich, H.T., Diehl, V., Gorgen, H., Pabst, T., Markova, J., Debus, J., Ho, A., Dorken, B., Rank, A., Grosu, A.L.,
Wiegel, T., Karstens, J.H., Greil, R., Willich, N., Schmidberger, H., Dohner, H., Borchmann, P., Muller-
Hermelink, H.K., Muller, R.P., and Engert, A. (2010a). Intensified chemotherapy and dose-reduced involvedfield
radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin
Study Group HD11 trial. J Clin Oncol 28, 4199-4206.
Eich, H.T., Engenhart-Cabillic, R., Hansemann, K., Lukas, P., Schneeweiss, A., Seegenschmiedt, H.,
Skripnitchenko, R., Staar, S., Willich, N., and Muller, R.P. (2008a). Quality control of involved field
radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma: an
analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 71, 1419-1424.
Eich, H.T., Kriz, J., and Muller, R.P. (2011). Evolution of radiation therapy within the German Hodgkin Study
Group trials. J Natl Compr Canc Netw 9, 1073-1080.
Eich, H.T., Muller, R.P., Engenhart-Cabillic, R., Lukas, P., Schmidberger, H., Staar, S., and Willich, N. (2008b).
Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German
Hodgkin Study Group (GHSG). Strahlenther Onkol 184, 406-410.
Eich, H.T., Zimmermann, C., and Müller, R.P. (2010b). Involved-Node-Radiotherapie in frühen Stadien des
Hodgkin-Lymphoms. Der Onkologe 16, 35-40.
Eichenauer, D.A., Fuchs, M., Pluetschow, A., Klimm, B., Halbsguth, T., Boll, B., von Tresckow, B., Nogova, L.,
Borchmann, P., and Engert, A. (2011). Phase 2 study of rituximab in newly diagnosed stage IA nodular
lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 118,
4363-4365.
Emami, B., Lyman, J., Brown, A., Coia, L., Goitein, M., Munzenrider, J.E., Shank, B., Solin, L.J., and Wesson,
M. (1991). Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21, 109-122.
Engert, A. (2010). Aktuelle Therapiestrategien der Deutschen Hodgkin Studiengruppe (GHSG). Der Onkologe
16, 28-34.
Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., Muller-Hermelink, K., and Diehl,
V. (2005). Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the
German Hodgkin's Study Group. J Clin Oncol 23, 5052-5060.
Engert, A., Diehl, V., Franklin, J., Lohri, A., Dorken, B., Ludwig, W.D., Koch, P., Hanel, M., Pfreundschuh, M.,
Wilhelm, M., Trumper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Muller-Hermelink, H.K.,
Hasenclever, D., and Loffler, M. (2009a). Escalated-dose BEACOPP in the treatment of patients with advancedstage
Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27, 4548-4554.
Engert, A., Eichenauer, D.A., Dreyling, M., and Group, O.b.o.t.E.G.W. (2009b). Hodgkin's lymphoma: ESMO
Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20, iv108-iv109.
Engert, A., Franklin, J., Eich, H.T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., Sieber,
M., Tesch, H., Franke, A., Koch, P., de Wit, M., Paulus, U., Hasenclever, D., Loeffler, M., Muller, R.P., Muller-
Hermelink, H.K., Duhmke, E., and Diehl, V. (2007). Two cycles of doxorubicin, bleomycin, vinblastine, and
dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's
lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25, 3495-3502.
125